| Name | Title | Contact Details |
|---|
We Are The Immune System Company™ In 1998, Founders David and Bianca Lisonbee embarked on a journey to bring 4Life Transfer Factor® products to the world. Everything we do at 4Life is guided by our 4 Values: Science, Success, Service, and Satisfaction.
AudioNet is a National Provider Network that sub-contracts with various Hearing Aid networks throughout the country to give eligible members the best selection of product and service under one network administrator. We have successfully sub-contracted with over 5,000 Audiologists/ENTs nationally to meet the contractual requirements of our customers, as well as the members needs. Mandating only the most qualified providers to service our members and monitoring the quality of products rendered, AudioNet is able to bring a level of Provider Accountability to the Hearing Aid industry that has never before been seen. Negotiating for State of the Art digital products within a National Provider Network allows the eligible member a tremendous benefit enhancement of upto Two (2) Standard Digital Hearing Aids, covered in full. The Fee Schedules, Product Models and Styles, etc., approved for distribution In-Network are outlined on this website.
Orgain, Inc. was founded by Andrew Abraham M.D. in 2008 . Orgain is the world's first organic drinkable meal on-the-go and is used by physicians, top nutritionists, professional athletes, and health conscious consumers across the nation. Orgain is nationally distributed at Whole Foods, Wegman's, Walgreens, CVS, Rite-Aid, Sprouts, Vitamin Shoppe, Mother's Market, Fairway Markets and many more -- over 15,000 retailers!
Commonwealth Health Corporation (CHC), headquartered in Bowling Green, Ky., was formed in 1984 as a not-for-profit holding company for The Medical Center at Bowling Green and other health-related businesses. CHC has since grown to be an expansive
T3D Therapeutics` mission is to develop its lead drug product candidate, T3D-959, as a potential `First-in-Class`and `Best-in-Class` disease-modifying, breakthrough medicine for the treatment of Alzheimer`s disease with the potential to slow, stop or reverse the course of the disease. The Company is also seeking to maximize the therapeutic utility of T3D=959 and has initiated pre-clinical studies in Huntington’s Disease models.